JP2025102775A5 - - Google Patents
Info
- Publication number
- JP2025102775A5 JP2025102775A5 JP2025034340A JP2025034340A JP2025102775A5 JP 2025102775 A5 JP2025102775 A5 JP 2025102775A5 JP 2025034340 A JP2025034340 A JP 2025034340A JP 2025034340 A JP2025034340 A JP 2025034340A JP 2025102775 A5 JP2025102775 A5 JP 2025102775A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical combination
- administering
- antibody
- dexamethasone
- lenalidomide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962809070P | 2019-02-22 | 2019-02-22 | |
| US62/809,070 | 2019-02-22 | ||
| US201962829814P | 2019-04-05 | 2019-04-05 | |
| US201962829791P | 2019-04-05 | 2019-04-05 | |
| US201962829804P | 2019-04-05 | 2019-04-05 | |
| US62/829,804 | 2019-04-05 | ||
| US62/829,791 | 2019-04-05 | ||
| US62/829,814 | 2019-04-05 | ||
| JP2021549416A JP7721445B2 (ja) | 2019-02-22 | 2020-02-21 | Ｃｄ３８に特異的に結合する抗体、レナリドミド、及びデキサメタゾンの組み合わせを用いて、新たに診断された多発性骨髄腫を治療する方法 |
| PCT/IB2020/051484 WO2020170211A1 (en) | 2019-02-22 | 2020-02-21 | Methods of treating newly diagnosed multiple myeloma with a combination of an antibody that specifically binds cd38, lenalidomide and dexamethasone |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549416A Division JP7721445B2 (ja) | 2019-02-22 | 2020-02-21 | Ｃｄ３８に特異的に結合する抗体、レナリドミド、及びデキサメタゾンの組み合わせを用いて、新たに診断された多発性骨髄腫を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025102775A JP2025102775A (ja) | 2025-07-08 |
| JP2025102775A5 true JP2025102775A5 (OSRAM) | 2026-01-09 |
Family
ID=72141407
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549416A Active JP7721445B2 (ja) | 2019-02-22 | 2020-02-21 | Ｃｄ３８に特異的に結合する抗体、レナリドミド、及びデキサメタゾンの組み合わせを用いて、新たに診断された多発性骨髄腫を治療する方法 |
| JP2025034340A Pending JP2025102775A (ja) | 2019-02-22 | 2025-03-05 | Ｃｄ３８に特異的に結合する抗体、レナリドミド、及びデキサメタゾンの組み合わせを用いて、新たに診断された多発性骨髄腫を治療する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549416A Active JP7721445B2 (ja) | 2019-02-22 | 2020-02-21 | Ｃｄ３８に特異的に結合する抗体、レナリドミド、及びデキサメタゾンの組み合わせを用いて、新たに診断された多発性骨髄腫を治療する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20200268847A1 (OSRAM) |
| EP (1) | EP3927376A4 (OSRAM) |
| JP (2) | JP7721445B2 (OSRAM) |
| CN (1) | CN113727729A (OSRAM) |
| CA (1) | CA3131064A1 (OSRAM) |
| WO (1) | WO2020170211A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| EA202092609A1 (ru) | 2014-12-04 | 2021-10-29 | Янссен Байотек, Инк. | Антитела к cd38 для лечения острого миелолейкоза |
| CA2986594C (en) | 2015-05-20 | 2025-06-10 | Tufts Medical Center, Inc. | Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
| HUE053366T2 (hu) | 2015-11-03 | 2021-06-28 | Janssen Biotech Inc | Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk |
| US20190233533A1 (en) | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| CN111565751A (zh) | 2017-10-31 | 2020-08-21 | 詹森生物科技公司 | 治疗高危多发性骨髓瘤的方法 |
| WO2023209555A1 (en) | 2022-04-26 | 2023-11-02 | Aragon Pharmaceuticals, Inc. | Approved drug products and methods for treating prostate cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9732154B2 (en) * | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| JP6600651B2 (ja) * | 2014-06-16 | 2019-10-30 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | 骨髄腫の治療 |
| US10617757B2 (en) * | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| US20170044265A1 (en) * | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
-
2020
- 2020-02-21 CN CN202080015963.2A patent/CN113727729A/zh active Pending
- 2020-02-21 JP JP2021549416A patent/JP7721445B2/ja active Active
- 2020-02-21 US US16/797,301 patent/US20200268847A1/en active Pending
- 2020-02-21 CA CA3131064A patent/CA3131064A1/en active Pending
- 2020-02-21 EP EP20759735.2A patent/EP3927376A4/en active Pending
- 2020-02-21 WO PCT/IB2020/051484 patent/WO2020170211A1/en not_active Ceased
-
2025
- 2025-03-05 JP JP2025034340A patent/JP2025102775A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022523372A5 (OSRAM) | ||
| US12435138B2 (en) | Immunotoxins, formulations thereof and their use in medicine | |
| JP6278224B2 (ja) | Ｐｄ−１アゴニストからなる自己免疫疾患治療剤 | |
| CN103533943B (zh) | 由cd3特异性结合结构域导致的不良作用的预防 | |
| JP2025011257A (ja) | Ｉｌ－４ｒ阻害剤の投与によるアレルギー処置方法およびアレルゲン特異的免疫療法の向上方法 | |
| TWI890481B (zh) | 雙特異性抗體 | |
| JP2011504872A5 (OSRAM) | ||
| CN114173819A (zh) | 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法 | |
| JP7783183B2 (ja) | 自己免疫障害における抗ｂｃｍａ治療 | |
| CN112969711B (zh) | 使用克拉扎珠单抗脱敏和改善hla致敏患者中的肾脏移植 | |
| Corbaux et al. | Bullous diseases | |
| Holle et al. | ANCA-associated vasculitides: pathogenetic aspects and current evidence-based therapy | |
| JP2024532438A5 (OSRAM) | ||
| WO2023130081A1 (en) | Method of treating a tumor with a combination of il-7 protein and vegf antagonist | |
| US20240409656A1 (en) | Methods of treating cd20 expressing b-cell cancers | |
| JP2024540304A5 (OSRAM) | ||
| JP2021505545A (ja) | 造血細胞移植後の急性移植片対宿主病の発症のリスクを低減する方法 | |
| Pham et al. | Anti-interleukin-6 receptor therapy with tocilizumab for refractory pseudophakic cystoid macular edema | |
| JP2024505923A5 (OSRAM) | ||
| JP2022537134A5 (OSRAM) | ||
| TW202019482A (zh) | Htlv-1關聯性脊髓病(ham)之治療或預防劑、及ham之治療方法 | |
| Lee et al. | High-Dose Intravenous Immunoglobulin to Treat Anti-Thymocyte Globulin Induction–Related BK Virus and Cytomegalovirus Infection in Patients with ABO-Incompatible Kidney Transplantation | |
| Nachman et al. | Developments in the immunotherapy of glomerular disease | |
| Kedar et al. | The role of intravenous immunoglobulins in the management of acute complex autoimmune conditions | |
| Reichenbach | A Sight for Sorre (l’s) Eyes |